Holly Elizabeth Rawizza MD
Research Fellow in Medicine, Brigham and Women's Hospital
Join to View Full Profile
Brigham and Women's Hospital75 Francis StreetBoston, MA 02115
Phone+1 617-432-4686
Dr. Rawizza is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General Hospital/Brigham and Women's HospitalFellowship, Infectious Disease, 2005 - 2008
Duke University HospitalResidency, Internal Medicine/Pediatrics, 2001 - 2005
Vanderbilt University School of MedicineClass of 2001
Certifications & Licensure
MA State Medical License 2007 - 2026
NC State Medical License 2001 - 2005
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
American Board of Pediatrics Pediatrics
Clinical Trials
- Dolutegravir Pharmacokinetics Among HIV/TB Coinfected Children Receiving Standard and High-dose Rifampicin Start of enrollment: 2023 Jul 07
Roles: Principal Investigator, Contact
- Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB Prevention Start of enrollment: 2024 Nov 15
Roles: Principal Investigator, Contact
Publications & Presentations
PubMed
- Patterns of peri-gestational weight change among women living with HIV in Nigeria receiving dolutegravir compared to alternative antiretroviral regimens: a retrospecti...Ammar Al Naimi, Charlotte Chang, Holly Rawizza, Oluwaseun Olaifa, Olabanjo Ogunsola
AIDS Research and Therapy. 2025-03-24 - Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy.Manna Semere Gebreyesus, Roeland E Wasmann, Helen McIlleron, Regina Oladokun, Prosper Okonkwo
Antimicrobial Agents and Chemotherapy. 2024-08-07 - Pretreatment and Acquired Drug Resistance in Children With Human Immunodeficiency Virus Type 1 in Jos, Nigeria.Augustine O Ebonyi, Jonathan Okpokwu, Holly Rawizza, Philippe Chebu, Beth Chaplin
Open Forum Infectious Diseases. 2024-03-01
Press Mentions
Dolutegravir Pharmacokinetics During Weekly Rifapentine/Isoniazid for TB PreventionFebruary 29th, 2024
Grant Support
- Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientistsBRIGHAM AND WOMEN'S HOSPITAL2024–2029
- Quantifying integrase resistance among Nigerian children failing dolutegravir to inform rapid diagnostic development in partnership with Nigerian scientistsBRIGHAM AND WOMEN'S HOSPITAL2024–2029
- Mind the gaps: Pharmacokinetic research to advance pediatric HIV/TB cotreatment and TB preventionBRIGHAM AND WOMEN'S HOSPITAL2022–2028
- Acquired HIV drug resistance among Nigerian children failing first-line ART: Implications for second-line dolutegravir useBRIGHAM AND WOMEN'S HOSPITAL2021–2025
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
